IP Library Granted Patent US 9,156,909
Granted Patent B2
US 9,156,909 · App. 14/031,963 · Granted Oct 13, 2015

Polynucleotides encoding IL-31 monoclonal antibodies

Inventors: Anthony W. Siadak (Kent, WA); Janine Bilsborough (Simi Valley, CA); Shirley Rene (Seattle, WA)
Assignee: ZymoGenetics, Inc.
C07K16/244A61K2039/505C07K2316/96C07K2317/34C07K2317/92Y10S514/885Y10S514/886
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,156,909
App. No.
14/031,963
Granted
Oct 13, 2015
Kind
B2
Abstract

The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.

Claims (11)

1. An isolated polynucleotide encoding a monoclonal antibody or antigen-binding fragment thereof that specifically binds to a polypeptide consisting of amino acid residues 27-164 of SEQ ID NO:2, wherein the monoclonal antibody or antigen-binding fragment thereof binds to the same epitope as the antibody produced by the hybridoma having ATCC Patent Deposit Designation PTA-6815 for binding to the polypeptide.

2. The polynucleotide of claim 1 , wherein the monoclonal antibody is the antibody produced by the hybridoma having ATCC Patent Deposit Designation PTA-6815.

3. The polynucleotide of claim 2 , wherein the monoclonal antibody is humanized.

4. The polynucleotide of claim 3 , wherein the humanized monoclonal antibody comprises a human immunoglobulin constant region.

5. The polynucleotide of claim 3 , wherein the isotype of the humanized monoclonal antibody is IgG.

6. The polynucleotide of claim 1 , wherein the antigen-binding fragment is a Fab, Fab′, F(ab′) 2 , or single chain Fv.

7. An isolated vector comprising the polynucleotide of claim 1 .

8. An isolated host cell comprising the vector of claim 7 .

9. A method of producing a monoclonal antibody or antigen-binding fragment thereof that specifically binds to a polypeptide consisting of amino acid residues 27-164 of SEQ ID NO:2 comprising:

a) culturing the host cell of claim 8 under conditions wherein the monoclonal antibody or antigen-binding fragment is expressed; and

b) recovering the monoclonal antibody or antigen-binding fragment.

Continuity (7)
Division 13185130 · Jul 18, 2011
Division 12420747 · Apr 8, 2009
Division 11430066 · May 8, 2006
Provisional Application 60678918 · May 6, 2005
Provisional Application 60696251 · Jul 1, 2005
Provisional Application 60711600 · Aug 26, 2005
Related Publication 20140080181A1 · Mar 20, 2014